Actavis Eyes Acquisitions In The Middle East And Niche Products In The U.S.
This article was originally published in PharmAsia News
Executive Summary
Possibly acquiring development expertise in biosimilars from the Swiss firm BioPartners is one of several strategic moves that newly appointed chief executive Claudio Albrecht is now making at the generics company Actavis
You may also be interested in...
Super Generics – The Next Step For Generic Players As Commoditized Drugs Yield Less Margins – DIA India Conference
It takes tremendous efforts but generic companies eye complex drugs for lasting gains, said DIA India speakers.
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics.